Evidence map›Paper›PMID 39932481›Full record

SynthesisHuman vaccines & immunotherapeutics2025

Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.

Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker and 7 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ariel BardachCenter for Research in Epidemiology and Public Health (CIESP-IECS), CONICET, Buenos Aires, Argentina.ORCID 0000-0003-4437-0073
Martin BrizuelaDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Mabel BerruetaDepartment of Mother and Child Health, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Agustín CiapponiArgentine Cochrane Center, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Juan M SambadeDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Jamile BallivianDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Vanesa OrtegaDepartment of Mother and Child Health, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Noelia CastellanaDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Daniel ComandéDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Edward P K ParkerThe Vaccine Centre, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.
Beate KampmannHealth Protection Research Unit in Immunisation, London School of Hygiene & Tropical Medicine, London, UK.
Katharina StegelmannDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Xu XiongSchool of Public Health and Tropical Medicine, Tulane University, New Orleans, USA.
Andy StergachisSchools of Pharmacy and Public Health, University of Washington, Seattle, USA.
Flor M MunozDepartments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Pierre BuekensSchool of Public Health and Tropical Medicine, Tulane University, New Orleans, USA.
Agustina MazzoniDepartment of Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.

Funding

Gates Foundation INV-008443
6 · The paper itself

Abstract

Chikungunya virus (CHIKV), transmitted through

Indexed as

Chikungunya FeverChikungunya virusViral VaccinesAdolescentChildFemaleHumansPregnancyVaccines, AttenuatedVaccines, AttenuatedViral Vaccinesadverse eventsChikungunyachildren and adolescentspregnant personsvaccine platformsvaccine safety

Identifiers

PMID39932481
PMCPMC11817526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.